ASCO GU 2017: Muscle-invasive bladder cancer: Molecular subtypes and response to neoadjuvant chemotherapy. - Session Highlights
Orlando, Florida USA (UroToday.com) There was much discussion and excitement at this year’s genitourinary cancer symposium regarding the ability of genomic classifiers to predict response to neoadjuvant chemotherapy. Through a fantastic demonstration of collaboration, molecular subtypes in bladder cancer based on gene expression have been widely accepted.
ASCO GU 2017: BC2001 long-term outcomes: A phase III randomized trial of chemoradiotherapy versus radiotherapy (RT) alone and standard RT versus reduced high-dose volume RT in muscle-invasive bladder cancer - Session Highlights
Orlando, Florida USA (UroToday.com) This year’s genitourinary cancer symposium allowed for Emma Hall to present long-term results from BC20001. Given that BC2001 showed that that reduced high dose volume RT rather than standard RT did not significantly reduce late side effects at limited follow up, the long term results have been anticipated [Huddart 2013].
ASCO GU 2017: Resection margins after radical cystectomy at academic versus community cancer centers. - Session Highlights
Orlando, Florida USA (UroToday.com) At this years genitourinary cancer symposium, the importance of high volume centers in care for radical cystectomy patients was re-inforced by looking at the impact of academic centers on positive margin rates. Positive margin resection correlates with worse overall survival following cystectomy.
ASCO GU 2017: Characterizing the costs of complications after cystectomy: Can we target the primary drivers? - Session Highlights
Orlando, Florida USA (UroToday.com) Dr. Matthew Mossanen from Brigham and Women’s Hospital targeted the thromboembolic events, soft tissue and GI complications as primary cost drivers following radical cystectomy. Motivation for this study stemmed from recognising the high complication rate of cystectomy being as high as 64% at 90 days and that radical cystectomy and care for bladder cancer as a whole is one of the more expenisive diseases to care for. This study looked at financial cost of different categories of complication following radical cystectomy to identify primary forces driving expenditures.
ASCO GU 2017: Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population. - Session Highlights
Orlando, Florida USA (UroToday.com) Until 2016, cisplatinum inelegible patients with advanced bladder cancer had poor outcomes due to limited effective therapies. This has been recognosied as an effective disease space for immunotherapies since recent FDA approval of checkpoint blockade for bladder cancer.
ASCO GU 2017: Health-related quality of life (HRQoL) in the KEYNOTE-045 study of pembrolizumab versus investigator-choice chemotherapy for previously treated advanced urothelial cancer - Session Highlights
Orlando, Florida USA (UroToday.com) The use of immunotherapy for advanced urothelial cancer continued to gain attention and excitement at this years genitourinary cancer symposium. Adding to this momentum is results from KEYNOTE-045 showing that pembrolizumab is better tolerated and more effective than standard cytotoxic chemotherapy.
ASCO GU 2017: Quality of care in non-muscle invasive bladder cancer: optimizing surgical and medical therapies - Session Highlights
Orlando, Florida USA (UroToday.com) Karim Chamie, UCLA, discussed the quality care for non-muscle invasive bladder cancer. There is a significant health burden associated with bladder cancer care.